Potential role of TNF alpha blockers in delaying the progression of hepato-renal syndrome

Medical Hypotheses

Volumn 78, Issue 2, 2012, Pages 225-226

  Tahir, Faryal ^a   Riaz, Haris ^b   Rehman, Anis ^c   Munir, Muhammad Bilal ^d  

^a DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^b CIVIL HOSPITAL   (Pakistan)

^c Al Barkat Welfare Medical Center   (Pakistan)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PENTOXIFYLLINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALCOHOL LIVER DISEASE; ARTICLE; CLINICAL PATHWAY; CONTROL GROUP; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG COST; HEPATORENAL SYNDROME; HUMAN; MORTALITY; PHYSICIAN; PROGNOSIS; STANDARD; SURVIVAL RATE; TREATMENT DURATION;

DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HEPATORENAL SYNDROME; HUMANS; LIVER FAILURE; PENTOXIFYLLINE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855186592     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.10.030     Document Type: Article

References (11)

1. Ng Charles K.F., Chan Michael H.M., Tai Morris H.L., Christopher W.K. Lam. Hepatorenal syndrome. Clin Biochem Rev 2007, 28:11-17.
2. Gines A., Escorsell A., Gines P., Salo J., Jimenez W., Inglada L., et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993, 105:229-236.
3. Wen Y., Wang J.Y., Liu P. Tumor necrosis factor-alpha enhances the effect of endothelin on renal vasoconstriction in isolated perfused rat kidney. Zhonghua Gan Zang Bing Za Zhi 2003, 11:583-585.
4. Akriviadis E., Botla R., Briggs W., Han S., Reynolds T., Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:1637-1648.
5. McHutchison J.G., Runyon B.A., Draguesku J.O., Cominelli F., Person J.L., Castracane J. Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology 1991, 14:96A.
6. De B.K., Gangopadhyay S., Dutta D., Baksi S.D., Pani A., Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009, 15:1613-1619.
7. Tyagi P., Sharma P., Sharma B.C., Puri A.S., Kumar A., Sarin S.K. Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo. Eur J Gastroenterol Hepatol 2011, 23:210-217.
8. Assimakopoulos S.F., Thomopoulos K.C., Labropoulou-Karatza C. Pentoxifylline: a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome?. World J Gastroenterol 2009, 15:3194-3195.
9. McCullough A.J., O'Connor J.F. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 1998, 93:2022-2036.
10. Mathurin P., Louvet A., Dharancy S. Treatment of severe forms of alcoholic hepatitis: where are we going?. J Gastroenterol Hepatol 2008, 23:S60-S62.
11. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.